Key result
A multimarker panel of cTnT, cTnI, NT-proBNP, and hsCRP demonstrated potential for predicting 2-year all-cause mortality and long-term risk stratification among patients with ESRD.
Why the study?
Does a multimarker panel of cardiac biomarkers improve risk stratification for mortality in patients with end-stage renal disease?
Does a multimarker panel of cardiac biomarkers improve risk stratification for mortality in patients with end-stage renal disease?
No takes yet. Share an insight, caveat, or question.
A multimarker panel of cardiac biomarkers shows promise for long-term risk stratification in ESRD patients, though appropriate renal-specific thresholds are required to avoid misleading 'false positive' interpretations.
Cameron et al. (2004) conducted an editorial in End-stage renal disease (ESRD) (n=399). Multimarker panel (cTnT, cTnI, NT-proBNP, and hsCRP) vs. Single-marker testing was evaluated on 2-year all-cause mortality. A multimarker panel of cTnT, cTnI, NT-proBNP, and hsCRP demonstrated potential for predicting 2-year all-cause mortality and long-term risk stratification among patients with ESRD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: